Figures & data
Figure 1 Schematic diagram representing MEK inhibitor-sensitive reactivation of MAPK signaling following BRAF inhibitor resistance.
Abbreviations: NF1, neurofibromin-1; RTK, receptor tyrosine kinase; MLK, mixed lineage kinases; ERK, extracellular-signal-regulated kinase; MAPK, mitogen-activated protein kinase.
![Figure 1 Schematic diagram representing MEK inhibitor-sensitive reactivation of MAPK signaling following BRAF inhibitor resistance.](/cms/asset/231b5d27-8556-465e-bd6e-c17aee4371a3/dddt_a_12177792_f0001_c.jpg)
Table 1 Summary of the clinical trials and outcome measures for combination vemurafenib and cobimetinib therapy
Figure 2 Schematic diagram representing aberrant signaling pathways responsible for resistance to BRAF or MEK inhibitors in metastatic melanoma and pharmacological strategies to overcome this resistance.
Abbreviations: PDGFR, platelet-derived growth factor receptor; IGF, insulin-like growth factor; ERK, extracellular-signal-regulated kinase.
![Figure 2 Schematic diagram representing aberrant signaling pathways responsible for resistance to BRAF or MEK inhibitors in metastatic melanoma and pharmacological strategies to overcome this resistance.](/cms/asset/f980ab4c-95f9-4ca3-a4d4-926a5cbc800f/dddt_a_12177792_f0002_c.jpg)